Table 1.
Patient characteristics for (1) Overall cohort, (2) children with no asthma diagnosis and (3) children with at least one asthma diagnosis
| Overall | No Asthma Diagnosis |
Asthma Diagnosis |
||
|---|---|---|---|---|
| Total Population | 161,502 | 126,924 | 34,578 | |
| Sex | Female | 78,882 (48%) | 64,837 (51%) | 14,045 (41%) |
| Race/Eth combined, n (%) | Non-Hispanic Asian | 5,763 (4%) | 4,863 (4%) | 900 (3%) |
| Non-Hispanic Black | 43,706 (30%) | 31,378 (28%) | 12,328 (38%) | |
| Hispanic | 10,533 (7%) | 8,231 (7%) | 2,302 (7%) | |
| Missing | 15,806 (10%) | 13,295 (11%) | 2,511 (7%) | |
| Other | 2,587 (2%) | 2,105 (2%) | 482 (2%) | |
| Non-Hispanic White | 83,107 (57%) | 67,052 (59%) | 16,055 (50%) | |
| Mean gestational age (GA), in months (sd) | 38.6 (2.3) | 38.7 (2.1) | 38.1 (3.0) | |
| Missing GA, n (%) | 32,648 (20%) | 24,584 (19%) | 8,064 (23%) | |
| GA <34 weeks, n (%) | 4,915 (4%) | 3,026 (3%) | 1,889 (7%) | |
| Medications*, n (%) | Albuterol | 60,182 (37%) | 28,735 (23%) | 31,447 (91%) |
| Inhaled Steroid | 11,090 (7%) | 1,555 (1%) | 9,535 (28%) | |
| Other asthma medication† | 3,931 (2%) | 1,555 (1%) | 2,376 (7%) | |
| Systemic Steroid | 27,635 (17%) | 15,237 (12%) | 12,398 (36%) | |
| Comorbidities*, n (%) | Allergic Rhinitis | 29,485 (18%) | 21,889 (17%) | 7,596 (22%) |
| Eczema | 65,409 (41%) | 50,337 (40%) | 15,072 (44%) | |
| Food Allergy | 9,963 (6%) | 7,294 (6%) | 2,669 (8%) | |
| Wheezing episode* n (%) | 64,687 (40%) | 32,811 (26%) | 31,876 (92%) | |
| Bronchiolitis diagnosis*, n (%) | 13,665 (9%) | 6,771 (5%) | 6,894 (20%) | |
| Cough diagnosis*, n (%) | 51,549 (32%) | 37,633 (30%) | 13,916 (40%) | |
| Proportion of visits at initial practice, median (IQR) | 0.94 (0.82 - 1.00) | 0.95 (0.84 - 1.00) | 0.90 (0.77 – 0.98) | |
*
indicates number of events occurring over entire observation interval for “No Asthma Diagnosis” group and number of events before asthma diagnosis for "Asthma Diagnosis" group
†
includes montelukast, zafirlukast, theophylline, aminophylline, dyphylline, omalizumab, reslizumab, mepolizumab